{"id":"clobex-spray","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypertrichosis"},{"rate":null,"effect":"Systemic corticosteroid absorption (with prolonged use or occlusion)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobetasol propionate, the active ingredient, binds to glucocorticoid receptors in skin cells and immune cells, reducing the production of inflammatory cytokines and mediators. This leads to decreased inflammation, itching, and skin lesion severity in inflammatory dermatological conditions. As a Class I (super-potent) corticosteroid, it is among the strongest topical steroids available.","oneSentence":"Clobex Spray is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:22.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., psoriasis, lichen planus, atopic dermatitis)"},{"name":"Severe inflammatory skin conditions requiring potent topical corticosteroid therapy"}]},"trialDetails":[{"nctId":"NCT01893567","phase":"PHASE4","title":"Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07","conditions":"Plaque Psoriasis","enrollment":28},{"nctId":"NCT00881868","phase":"PHASE4","title":"Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-04","conditions":"Scalp Psoriasis","enrollment":81},{"nctId":"NCT00733954","phase":"PHASE4","title":"Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-08","conditions":"Plaque Psoriasis","enrollment":250},{"nctId":"NCT00658788","phase":"PHASE3","title":"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-03","conditions":"Psoriasis","enrollment":305},{"nctId":"NCT00988637","phase":"PHASE4","title":"Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-10","conditions":"Plaque Psoriasis","enrollment":138},{"nctId":"NCT00437255","phase":"PHASE4","title":"Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08","conditions":"Plaque Psoriasis","enrollment":122},{"nctId":"NCT00436540","phase":"PHASE4","title":"A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-03","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT00437216","phase":"","title":"Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-02","conditions":"Psoriasis","enrollment":2488},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT03453190","phase":"PHASE4","title":"Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis","status":"UNKNOWN","sponsor":"Washington Dermatology Center","startDate":"2018-02-25","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT01012713","phase":"PHASE4","title":"Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-06","conditions":"Chronic Stable Plaque Psoriasis","enrollment":30},{"nctId":"NCT01205880","phase":"PHASE4","title":"Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis","status":"COMPLETED","sponsor":"Emer, Jason, M.D.","startDate":"2009-12","conditions":"Psoriasis","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"PSORIASIS"},{"count":4,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"COUGH"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"INJECTION SITE ERYTHEMA"},{"count":2,"reaction":"PAIN IN EXTREMITY"},{"count":2,"reaction":"PRURITUS"},{"count":1,"reaction":"ACUTE TONSILLITIS"},{"count":1,"reaction":"ARTHROPATHY"},{"count":1,"reaction":"ASTHENIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clobetasol propionate spray"],"phase":"marketed","status":"active","brandName":"Clobex Spray","genericName":"Clobex Spray","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobex Spray is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., psoriasis, lichen planus, atopic dermatitis), Severe inflammatory skin conditions requiring potent topical corticosteroid therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}